As shown inFigure S3, both genes had very low somatic mutation rates in different HCC datasets (SLC2A9: 0.82%, 2/243 in the INSERM; 0.27%, 1/366 in the TCGA PanCancer Atlas study; 0.27%, 1/373 in the TCGA Firehose Legacy study; and 0.43%, 1/231 in the AMC; SLC5A10: 0.41%, 1/243 in the INSERM; 0.55%, 2/366 in the TCGA PanCancer Atlas study; 0.54%, 2/373 in the TCGA Firehose Legacy study; and 0.43%, 1/231 in the AMC). The gene discussed is SLC2A9; the disease is hepatocellular carcinoma.